The arrival of Retatrutide ZPHC, at a concentration of 120mg, is sparking considerable interest within the weight loss community. This groundbreaking dual GIP and GLP-1 agonist medication suggests to provide significant improvements in weight reduction compared to existing therapies. Initial patient studies have shown substantial declines in body f